Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes.

doi:10.1016/j.euo.2025.01.002

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes.

European urology oncology - 1 Apr 2026

Raychaudhuri Ruben, Tuchayi Abuzar Moradi, Low Soon Khai, Arafa Ali T, Graham Laura S, Gulati Roman, Pritchard Colin C, Montgomery Robert B, Haffner Michael C, Nelson Peter S, Yu Evan Y, Hawley Jessica E, Cheng Heather H, Mo George, Chen Delphine L, Antonarakis Emmanuel S, Kilari Deepak, Hope Thomas A, Iravani Amir, Schweizer Michael T

Abstract excerpt

BACKGROUND AND OBJECTIVE: The prostate-specific membrane antigen (PSMA) radioligand 177Lu-PSMA-617 (LuPSMA) is approved for treatment of metastatic castration-resistant prostate cancer (mCRPC). PARP inhibitors (PARPi) are approved for patients with mCRPC and mutations in homologous recombination repair (HRR) pathway genes. Both modalities induce DNA damage and therefore may share mechanisms of resistance. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Dipeptides

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Prostate-Specific Antigen

Share to Prostatic Neoplasms, Castration-Resistant

Share to Recombinational DNA Repair

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 39920014
DOI: 10.1016/j.euo.2025.01.002
PMCID: PMC12325686

Genes

BRCA2
ATM

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes.PMID 39920014Read ↗

Association between DNA damage repair alterations and outcomes to 177Lu-PSMA-617 in advanced prostate cancerSemantic proximity Read ↗

Differential Response to 177Lu-PSMA-617 in Patients with Tumor Suppressor Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutationsSemantic proximity Read ↗

PARP Inhibitors in Prostate Cancer: Broad Use or Patient Selection?Semantic proximity Read ↗

PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.Semantic proximity Read ↗

PARP Inhibitors and Prostate Cancer: To Infinity and BeyondBRCASemantic proximity Read ↗

PARP Inhibition in Prostate Cancer With Homologous Recombination Repair AlterationsSemantic proximity Read ↗

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate CancerSemantic proximity Read ↗

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate CancersSemantic proximity Read ↗

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage SignaturesSemantic proximity Read ↗

A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer.Semantic proximity Read ↗

Rucaparib - drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.